Needleless syringe

Abstract

The present invention relates to a needleless syringe comprising: a main body part; a control part for controlling the main body part; a drug accommodation part connected to one end of the main body part; and a nozzle part through which a drug accommodated in the drug accommodation part is discharged, wherein the main body part provides, in a pulse form, pressure of a predetermined magnitude to the drug accommodated in the drug accommodation part so as to discharge, to the outside through a nozzle hole of the nozzle part, the drug accommodated in the drug accommodation part under the control of the control part, and further includes an electronic control valve which is disposed in a drug flow path communicating with each of the drug accommodation part and the nozzle part, so as to open / close the flow path of the drug. According to the present invention, the needleless syringe for injecting a drug through the application of pulse pressure can more reliably prevent external air from flowing into the nozzle part during drug discharge.

Description

Needleless syringe

[0001] The present invention relates to a needleless syringe, and more particularly, to a needleless syringe capable of repeatedly injecting a drug at high speed without an injection needle.

[0002] A syringe is a device used to inject a drug into the tissues of a living organism. A syringe consists of a needle, a syringe barrel that holds the drug, and a piston that reciprocates within the syringe barrel to force the drug into the needle. The needle has a hole through which the drug is injected.

[0003] However, in the case of diabetic patients who need to receive injections several times a day, they need to receive injections frequently even while receiving treatment at home rather than in a hospital. However, because of the pain when the needle penetrates the skin, it is difficult for them to inject themselves while receiving treatment at home rather than in a hospital.

[0004] Recently, research and development on needle-less syringes have been actively pursued to alleviate the fear of needles and prevent needle-borne infections.

[0005] However, since existing needleless syringes are designed to inject a certain amount of drug into only one part of the skin at a time, damage to skin tissue may occur.

[0006] In addition, because of the inconvenience of reloading after a single injection, there is a limitation in using it to evenly inject multiple drugs into a large area of ​​skin, such as in the field of skin beauty.

[0007] Accordingly, in order to solve these problems, the present inventors developed the needleless syringe disclosed in Patent Document 1. According to the needleless syringe disclosed in Patent Document 1, a piston that pressurizes and injects a drug is configured to repeatedly move back and forth using a power source such as a solenoid, thereby enabling a small amount of drug to be repeatedly injected at high speed and evenly injected into a wider area of ​​skin.

[0008] (Patent Document 1) Patent Document 1: Republic of Korea Patent No. 10-2088830 (March 9, 2020)

[0009] FIG. 8 is a drawing illustrating one embodiment of a needleless syringe disclosed in Patent Document 1.

[0010] As shown in FIG. 8, FIG. 8 is a drawing showing one embodiment of a needleless syringe disclosed in patent document 1.

[0011] As shown in Fig. 8, in the case of the needleless syringe disclosed in Patent Document 1, one solenoid coil (1a) is provided, and the piston (3) is moved forward by repeating the supply and cut-off of current to the solenoid coil (1a) at a preset cycle, and includes a current supply unit (not shown) and an elastic member that provides elasticity in the direction in which the piston (3) moves backward when the current supply to the current supply unit (not shown) is cut off.

[0012] Specifically, when the moving magnet (1b) advances a predetermined distance due to the magnetic force generated in the solenoid coil (1a), it collides with the piston head (3a) at the rear end of the piston (3), and the piston (3) advances due to the impact force at this time. Then, the springs (4a, 4b) are compressed by the advance of the piston (3), and when the current supply to the solenoid coil (1a) is stopped, the piston (3) retracts due to the compressive force of the springs (4a, 4b).

[0013] Meanwhile, a diaphragm (2b) is provided in front of the piston (3), and as the piston (3) moves backward, the diaphragm (2b) deforms, thereby reducing the pressure inside the valve chamber (7), and the drug is filled through the drug supply path (5a) extending from the drug charger (5) into the valve chamber (7) according to the pressure difference inside and outside the valve chamber (7). Then, as the piston (3) moves forward, the diaphragm (2b) deforms, thereby applying high pressure momentarily to the drug filled in the valve chamber (7), thereby causing the drug to be sprayed through the nozzle hole (2a) of the nozzle (2).

[0014] Meanwhile, a valve seat is formed in the middle of the valve chamber (7), and a check valve (8) is provided so that the drug flows only in one direction toward the nozzle portion (2a) through this valve seat. In the example shown in Fig. 8, the check valve (8) is provided with a ball pin and a spring that urges the ball pin toward the valve seat. As the piston (3) retracts, the diaphragm (2b) deforms and the drug is filled into the valve chamber (7), and the ball pin prevents outside air from entering the valve chamber (7) through the nozzle portion (2a) by urging the ball pin to the valve seat by the elastic force of the spring. In addition, as the piston (3) advances, the diaphragm (2b) deforms and the pressure inside the valve chamber (7) increases, and this pressure acts on the ball pin, causing the ball pin to overcome the elastic force of the spring and move forward, thereby allowing the drug filled inside the valve chamber (7) to be discharged to the outside through the nozzle portion (2a).

[0015] Meanwhile, FIG. 9 is a drawing explaining the flow of time from the start of pressurizing the drug in the valve chamber (7) to the completion of the jet injection of the drug in the needleless syringe illustrated in FIG. 10, and FIG. 10 is a photograph of the state inside the nozzle between the time when the check valve (8) closes and the completion of the jet injection of the drug in the needleless syringe illustrated in FIG. 8.

[0016] Referring to FIG. 9, when the diaphragm (2b) deforms as the piston (3) advances, the pressurization of the drug filled in the valve chamber (7) begins. At a time point of approximately 400 μs, the piston (3) reaches top dead center and pressurization is completed. After this, the piston (3) begins to move backward, the ball pin of the check valve (8) comes into contact with the valve seat, and the check valve (8) closes. At a time point of approximately 2590 μs from the start of pressurization, the discharge of the drug (100) at the target flow rate is completed. However, as illustrated in FIG. 10, it can be seen that external air is initiated to flow into the nozzle portion (2a) at a time point of approximately 1570 μs between the time point of completion of the jet ejection of the drug and the time point of completion of the jet ejection of the drug, even though the reverse flow has already been blocked by the check valve (8). That is, it can be seen that air is still flowing into the nozzle part (2a) even though the check valve (8) is closed.

[0017] The present invention has been devised to solve the above-mentioned problem, and the purpose of the present invention is to provide a needleless syringe that can prevent external air from entering the nozzle section between the time when pressurization of the drug inside the valve chamber is completed and the time when the jet of the drug is completed.

[0018] In order to solve the above-described problem, the needleless syringe according to the present invention comprises a main body, a control unit for controlling the main body, a drug receiving portion connected to one end of the main body, and a nozzle unit for discharging a drug contained in the drug receiving portion, wherein the main body further comprises an electronic control valve configured to provide a pressure of a predetermined magnitude in the form of pulses to a drug contained in the drug receiving portion so that the drug contained in the drug receiving portion is discharged to the outside through a nozzle hole of the nozzle unit under the control of the control unit, and to open and close the drug receiving portion and the nozzle unit, respectively, in a drug path communicating with the drug receiving portion and the nozzle unit.

[0019] Preferably, the control unit can control the electronic control valve to close the drug passage by transmitting a control signal to the electronic control valve at the same time as or before the pressurization of the drug according to the pulse-type pressure is completed.

[0020] Preferably, the electronic control valve is configured to be detachably attached to the drug receiving portion and the nozzle portion, respectively, and the electronic control valve may have an internal passage forming a drug flow path therein, one end of which is in fluid communication with the internal chamber of the drug receiving portion, and the other end of which is in fluid communication with the nozzle hole of the nozzle portion.

[0021] Preferably, one end and the other end of the inner tube may be formed with a male or female screw portion for screw-connection with the female or male screw portion formed in the nozzle portion and the drug receiving portion, respectively.

[0022] Preferably, the electronic control valve includes a first core formed of a magnetic material and a solenoid coil arranged to surround the first core, and the first core can be configured to move forward and backward in a direction transverse to the internal passage according to the direction of a current applied to the solenoid coil to open and close the internal passage.

[0023] Preferably, the first core may further have a sealing portion at the tip along the direction of entry into the internal passage to absorb impact when the first core and the internal passage come into contact to close the internal passage.

[0024] Preferably, the first core may have a hollow inner space formed at one end thereof that is open toward the inner passage, and a second core may be accommodated in the inner space, and the second core may include an elastic member having one end connected to the inner space and the other end connected to one end of the second core.

[0025] Preferably, the other end of the second core may be configured to contact the inner wall of the inner passage when the first core enters the inner passage and closes the inner passage.

[0026] Preferably, the other end of the second core may further include a sealing portion to absorb impact when the second core and the inner filament come into contact.

[0027] Preferably, the nozzle portion is directly connected to the drug receiving portion, the electronic control valve is configured to be detachably attached to the nozzle portion, and a first passage is formed inside the nozzle portion, one end of which communicates with the drug receiving portion and the other end of which communicates with a nozzle hole of the nozzle portion, and the electronic control valve can be configured to open and close the flow path of the first passage.

[0028] Preferably, the nozzle portion has a second passage extending in a direction transverse to the first passage, one end of which is in communication with the first passage, and the other end of which is in communication with the electronic control valve, and the electronic control valve includes a first core formed of a magnetic material and a solenoid coil provided to surround the first core, and the first core can be configured to move forward and backward in a direction transverse to the first passage through the second passage according to the direction of a current applied to the solenoid coil to open and close the first passage.

[0029] Preferably, the first core may further have a sealing portion at the tip along the direction of entry into the first passage to absorb impact when the first core and the first passage come into contact to close the first passage.

[0030] Preferably, the first core has a hollow inner space formed at one end thereof that is open toward the first passage, and a second core is accommodated in the inner space, and the second core includes an elastic member having one end connected to the inner space and the other end connected to one end of the second core, and the other end of the second core can be configured to be in contact with the inner wall of the first passage when the first core enters the inner passage and closes the first passage.

[0031] Preferably, the other end of the second core may further include a sealing portion to absorb impact when the second core and the inner filament come into contact.

[0032] Preferably, a one-way check valve may be provided on the drug flow path so that the drug contained in the chamber of the drug receiving portion flows only in one direction toward the nozzle portion.

[0033] Preferably, the nozzle portion can be detachably mounted to the drug receiving portion.

[0034] Preferably, the drug receptacle can be detachably mounted on one end of the main body.

[0035] Preferably, the sealing portion can perform a sealing function to prevent leakage of the drug through the drug passage when the drug passage is closed through an electronic control valve.

[0036] According to the present invention described above, by using an electronic control valve with a fast response time, external air can be more reliably blocked from entering the nozzle section during the drug dispensing process compared to a conventional needleless syringe that only uses a check valve using a ball pin and an elastic member.

[0037] According to the present invention described above, the drug receiving portion and the main body are configured to be detachable, and the drug receiving portion and the electronic control valve are configured to be detachable, so that the main body and the electronic control valve are permanent parts, while only the drug receiving portion can be configured as a consumable part, so that by replacing only the drug receiving portion, the user can easily switch the type of drug discharged from the needleless syringe.

[0038] FIG. 1 is a configuration diagram of a needleless syringe according to the present invention. FIG. 1 is a configuration diagram of a needleless syringe according to the present invention.

[0039] Figure 2 is an enlarged partial view of the drug receiving portion and electronic control valve portion of the needleless syringe illustrated in Figure 1.

[0040] Figures 3a and 3b are drawings explaining the euro opening and closing operation using the control valve illustrated in Figure 1.

[0041] FIG. 4 is a drawing for explaining the combined form of the drug receiving portion and the electronic control valve of the needleless syringe shown in FIG. 1.

[0042] Fig. 5 is a drawing for explaining the opening and closing timing of the electronic control valve of the needleless syringe illustrated in Fig. 1.

[0043] FIG. 6 is an enlarged partial view of a drug receiving portion and an electronic control valve portion of a needleless syringe according to another preferred embodiment of the present invention.

[0044] FIG. 7a and FIG. 7b are drawings explaining the euro opening and closing operation using the electronic control valve illustrated in FIG. 6.

[0045] Figure 8 is a drawing showing the structure of a conventional needleless syringe.

[0046] FIG. 9 is a drawing explaining the flow of time from the start of pressurizing the drug in the valve chamber to the completion of spraying the jet of the drug in the needleless syringe illustrated in FIG. 8.

[0047] Fig. 10 is a photograph of the state inside the nozzle of the needleless syringe illustrated in Fig. 8 between the time when the check valve (8) closes and the time when the jet of the drug is completed.

[0048]

[0049] What each symbol represents is as follows:

[0050] 1: Body 1a: Solenoid coil

[0051] 2a: Nozzle section 2b: Diaphragm

[0052] 2c: Main Hall 3: Piston

[0053] 3a: Piston head 3b: Spring

[0054] 3c: Flange 4a: Fixed blocker

[0055] 4b: Length-adjusting blocker 5: Drug charger

[0056] 5a: Drug supply hole 6: Nozzle opening / closing valve

[0057] 7: Valve chamber 8: Check valve

[0058] 10: Main body 10a: Main body housing

[0059] 11: Solenoid coil 12: Motion magnet

[0060] 13: Piston 20: Drug container

[0061] 20a: Drug receiving unit housing 21, 21a: Chamber

[0062] 23: Ball pin 24: Spring

[0063] 25: Connection part 26: Male screw part

[0064] 30: Nozzle part 31: Nozzle hole

[0065] 32: Aisle 1 33: Aisle 2

[0066] 34: First connection 40: Electronic control valve

[0067] 41: Solenoid coil 43: First core

[0068] 43a: Sealing part 43b: Elastic member

[0069] 44: Second core 46: Fluid passage

[0070] 46a, 46b: Female thread 47: Internal flow

[0071] 48: Second connector 50: Drug charging station

[0072] 51: Drug supply hole 100: Drug

[0073] 110: Outside air

[0074]

[0075] Hereinafter, with reference to the attached drawings, a preferred embodiment of a needleless syringe according to the present invention will be described in detail. Hereinafter, with reference to the attached drawings, a preferred embodiment of a needleless syringe according to the present invention will be described in detail.

[0076] Fig. 1 is a schematic diagram of a needleless syringe according to the present invention, and Fig. 2 is an enlarged partial view of the drug receiving portion and control valve portion of the needleless syringe illustrated in Fig. 1. As illustrated in Fig. 1, the needleless syringe according to the present invention comprises a main body portion (10), a drug receiving portion (20), and an electronic control valve (40) equipped with a nozzle portion (30) as a control valve.

[0077] The main body (10) provides a pulse reciprocating motion of the moving magnet (12) provided inside the main body (10) by a driving force generated from a predetermined power source. In the example shown in Fig. 1, the main body (10) is provided with a solenoid coil (11) on the outer periphery, and provides a pulse reciprocating motion of the moving magnet (12) by periodically changing the direction of the current applied to the solenoid coil (11). When the moving magnet (12) moves forward by the magnetic field formed by the current applied to the solenoid coil (11), it collides with the piston (13) at the front, and as the piston (13) moves forward due to this collision, it applies a predetermined pressure to the drug in the drug container (20) described later. In addition, a spring (14) is provided as an elastic member on the inner wall of the main body (10) and the other end of the piston (13), and applies a force so that the piston (13) moves forward by a predetermined distance and then moves back to its original position. However, the example illustrated in FIG. 1 is merely a preferred embodiment of the present invention, and there are no limitations as long as the configuration can apply a predetermined pulse pressure to the drug filled inside the drug receiving portion (10). For example, a configuration that generates power using compressed air or a spring and a motor instead of a solenoid coil may be used.

[0078] The drug receiving portion (20) is configured to discharge the drug inside to the nozzle portion by using the pressure generated by the driving force in the main body (10) while the drug is filled inside. The drug receiving portion (20) may be configured to be integrally formed at one end of the main body (10) and directly connected to the main body (10), or may be configured separately from the main body (10) and connected to the main body (10) through a predetermined connecting means.

[0079] In the example shown in FIGS. 1 and 2, a diaphragm (22) is provided inside the drug receiving portion (20) in front of the piston (13), and as the piston (13) moves backward, the diaphragm (22) deforms, thereby lowering the pressure inside the chamber (21) of the drug receiving portion (10), and depending on the pressure difference inside and outside the chamber (21), the drug solution is filled through the drug supply hole (51) extending from the drug filling device (50) into the chamber (21) of the drug receiving portion (20). Then, as the piston (13) moves forward, the diaphragm (22) deforms, thereby applying high pressure momentarily to the drug solution filled in the chamber (21) of the drug receiving portion (20), thereby causing the drug solution to be discharged forward.

[0080] Meanwhile, a valve seat is formed in the middle inside the chamber (21) of the drug receiving portion (20), and a check valve is provided so that the drug flows only in one direction toward the nozzle portion (30) so that external air does not enter the nozzle portion when the diaphragm (22) is deformed and the drug is filled into the chamber (21) of the drug receiving portion (20). In the example shown in Fig. 2, the check valve is composed of a ball pin (23) and a spring (24) that presses the ball pin (23) toward the valve seat. As the piston (13) retracts and the diaphragm (22) is deformed and the drug is filled into the drug receiving portion (20), the ball pin (23) presses the ball pin (23) toward the valve seat by the elastic force of the spring (24), thereby preventing external air from entering the drug receiving portion (20) through the nozzle portion (30). And, when the diaphragm (22) is deformed as the piston (13) moves forward, the pressure inside the drug receiving portion (20) increases, and this pressure acts on the ball pin (23), so that the ball pin (23) overcomes the elasticity of the spring (24) and moves forward, thereby causing the drug filled inside the drug receiving portion (20) to be discharged to the outside through the nozzle portion (30) via the electronic control valve (40). However, the check valve composed of the ball pin (23) and the spring (24) that presses the ball pin (23) toward the valve seat as described above is an optional configuration, and instead of this check valve, the electronic control valve (40) described below is controlled so that when the piston (14) descends, the electronic control valve (40) blocks the flow path, thereby replacing the function of the check valve that prevents external air from entering during drug filling.

[0081] The electronic control valve (40) receives a control signal from a control unit (not shown) and operates to perform the function of allowing or blocking the flow of the drug between the drug receiving unit (20) and the nozzle unit (30).

[0082] FIG. 3a and FIG. 3b are drawings explaining the euro opening and closing operation using the electronic control valve illustrated in FIG. 1.

[0083] In the example shown in FIGS. 3A and 3B, the electronic control valve (40) has, for example, a first core (44) formed of a magnetic material therein and a solenoid coil (41) arranged to surround the first core (44). An internal passage (47) is formed inside the electronic control valve (40), one end of which communicates with the drug receiving portion (20) and the other end of which communicates with the nozzle portion (30). Preferably, a hollow internal space is formed in the first core (44) that can accommodate a second core (43) therein and has an open bottom, so that the second core (43) is accommodated in the internal space. A sealing portion (43a) extending across the internal passage (47) is formed at one end of the second core (43), and one end of an elastic member (43b) such as a spring is connected to the other end of the second core (43). The other end of the elastic member (43b) is connected to the internal space of the first core (44). The elastic member (43b) performs the function of absorbing shock when the sealing portion (43a) of the second core (43) comes into contact with the inner wall of the internal passage. However, the present invention is not limited to this embodiment, and as illustrated in FIG. 6, the sealing portion (43a) may be formed directly on the first core (44) without the presence of the second core (43), or the first core (44) itself may perform the function of the sealing portion.

[0084] Meanwhile, as illustrated in FIG. 3a, when current flows in the direction in which the first core (44) descends in the solenoid coil (41), the second core (43) descends along with the descending of the first core (44), and the sealing portion (43a) of the second core (43) comes into contact with the inner wall of the internal passage, thereby blocking the internal passage (47). On the other hand, as illustrated in FIG. 3b, when current flows in the direction in which the first core (44) ascends in the solenoid coil (41), the second core (43) rises along with the ascending of the first core (44), and the sealing portion (43a) of the second core (43) separates from the inner wall of the internal passage, thereby allowing the internal passage to be connected. As described above, when the internal flow path (47) is blocked, the sealing portion (43a) comes into contact with the inner wall of the internal flow path (47), and the sealing portion (43a) also performs the function of preventing the drug from leaking through the gap between the second core (43) and the internal flow path (47) when the internal flow path (47) is blocked.

[0085] The end of the drug receiving portion (20) of the internal passage (47) is formed so that the electronic control valve (40) can be attached to and detached from the drug receiving portion (20). In the examples shown in FIGS. 2 and 3A, for this purpose, a female screw portion (46a) is formed on the inner wall of the end of the drug receiving portion (20) of the internal passage (47), and as shown in FIG. 4, the end of the electronic control valve (40) of the housing forming the drug receiving portion (20) has a protruding connection portion (25) having an outer peripheral shape that can be inserted into the internal passage (47), and a male screw portion (26) is formed on the outer peripheral surface of the connection portion (25). Therefore, the electronic control valve (40) and the drug receiving portion (20) can be easily attached and detached by relatively rotating them. In addition, when the drug receiving portion (20) is configured to be detachable from the main body housing (10a) of the main body (10), the drug receiving portion (20) and the main body (10) can be easily attached and detached by relatively rotating them. Through this, as shown in FIG. 2, the main body (10) and the electronic control valve (40) can be configured as permanent parts, and only the drug receiving portion (20) in which the drug is received can be configured as a separate consumable part. In this case, when a user needs to inject a different drug into the skin, he or she can easily replace the drug by selecting only the drug receiving portion in which the corresponding drug is injected and connecting it to the main body (10) and the electronic control valve (40), respectively. Meanwhile, in the examples shown in FIGS. 3a and 4, a female screw portion (46a) is formed on the inner wall of the drug-receiving portion (20) side end of the internal flow path (47), and the electronic control valve (40) side end of the housing forming the drug-receiving portion (10) has an outer peripheral shape that can be inserted into the internal flow path (47) and a male screw portion (26) is formed on the outer peripheral surface thereof. However, the present invention is not limited to the above-described embodiment. For example, a male screw portion may be formed on the outer peripheral side of the outer wall of the internal flow path (47), and a female screw portion may be formed on the inner peripheral wall surface of the housing of the drug-receiving portion (20).

[0086] Meanwhile, in the examples shown in FIGS. 2 and 3a, a female screw portion (46b) is formed on the inner wall of the nozzle-side end of the internal flow path (47) for this purpose, and as shown in FIG. 2, a male screw portion (32) is formed on the outer periphery of the electronic control valve (40)-side end of the housing forming the nozzle portion (30). Therefore, the electronic control valve (40) and the nozzle portion (30) can be easily attached and detached by rotating them relative to each other. Therefore, when a problem occurs in the nozzle portion (30), the user can easily replace only the nozzle portion (30). However, the present invention is not limited to the above-described embodiment, and the nozzle portion (30) may be formed integrally with the electronic control valve (40) so that both function as permanent parts.

[0087] Fig. 5 is a drawing for explaining the opening and closing timing of the electronic control valve of the needleless syringe illustrated in Fig. 1.

[0088] Referring to FIG. 5, when performing micro-jet injection using a needleless syringe according to the present invention, the electronic control valve (40) first operates as illustrated in FIG. 3b to open the internal flow path (47). Next, pressure is applied to the drug contained in the drug receiving portion (20), for example, by moving the piston (13) of the main body (10) forward. Then, at the same time as the piston (13) reaches the top dead center and pressurization of the drug is completed, or immediately before pressurization is completed, a control unit (not illustrated) transmits a control signal to the electronic control valve (40), thereby operating the electronic control valve (40) as illustrated in FIG. 3b to close the internal flow path (47). To this end, it is preferable to have an encoder (not shown) capable of detecting the real-time position of the piston (13) within the main body (10), and when the piston (13) advances and retreats, the position per hour of the piston (13) is detected by the encoder, and the result detected by the encoder is transmitted to the control unit. Through this, the control unit can determine whether the piston (13) has reached the top dead center, and transmit a control signal to the electronic control valve (40) at the time when it is determined that the piston (13) has reached the top dead center, so as to close the internal flow path (47).

[0089] After the internal passage (47) is closed by the electronic control valve (40), the piston (13) reaches the top dead center, pressurization of the drug is completed, and after a predetermined time has elapsed, the microjet ejection is completed. In this way, the needleless syringe according to the present invention employs a solenoid-type electronic control valve (40) to close the valve simultaneously with or earlier than the time when pressurization of the drug is completed through passage opening and closing control utilizing a fast response time. Through this, it is possible to fundamentally prevent external air from flowing into the interior through the nozzle portion (30) during the microjet ejection process of the drug.

[0090] FIG. 6 is an enlarged partial view of a drug receiving portion and an electronic control valve portion of a needleless syringe according to another preferred embodiment of the present invention.

[0091] The difference between the embodiment illustrated in FIG. 6 and the embodiment illustrated in FIG. 2 is that in the embodiment illustrated in FIG. 2, the nozzle part (30) is connected to the drug receiving part (20) through an electronic control valve (40), whereas in the embodiment illustrated in FIG. 6, the nozzle part (30) is directly connected to the drug receiving part (20) so that the two form a disposable part as a single unit, and the electronic control valve (40) is configured as a permanent part that is detachably connected to the nozzle part (30).

[0092] To this end, a first passage (32) is formed inside the nozzle unit (30), one end of which is directly connected to the chamber (21a) inside the drug receiving unit (20), and the other end is connected to the nozzle hole (31) of the nozzle unit (30), and a second passage (33) is formed that penetrates the first passage (32) and extends in a direction perpendicular to the first passage (32). In addition, a second connection portion (48) formed at the tip of the electronic control valve (40) and a detachable first connection portion (34) are provided on the outer periphery of the nozzle unit (30). In the example shown in FIG. 6, the first connection portion (34) has a female screw portion formed on the inner periphery of a space sunken into the inside of the nozzle unit (30) and a male screw portion formed on the outer periphery of the second connection portion (48) at the tip of the electronic control valve (40), but the present invention is not limited thereto. Accordingly, the first connection part (34) on the outer circumference side of the nozzle part (30) may be configured as a male screw part formed on the outer circumference of the protrusion, and a female screw part may be formed on the inner circumference side of the second connection part (48) of the electronic control valve (40).

[0093] FIG. 7a and FIG. 7b are drawings explaining the euro opening and closing operation using the electronic control valve illustrated in FIG. 6.

[0094] As illustrated in FIG. 7a, when current flows in the direction in which the first core (43) descends in the solenoid coil (41), the first core (43) descends along the second passage (33), and the sealing portion (43a) formed in the first core (43) blocks the first passage (32), thereby blocking the fluid flow from the drug receiving portion (20) to the nozzle portion (30). On the other hand, as illustrated in FIG. 7b, when current flows in the direction in which the first core (43) ascends in the solenoid coil (41), the first core (43) ascends along the second passage (33), and the sealing portion (43a) of the first core (43) opens the first passage (32), thereby allowing the fluid flow from the drug receiving portion (20) to the nozzle portion (30).

[0095] The present invention relates to a needleless syringe that uses a pulse-shaped pressure applied from a main body to inject a drug contained in a drug container from a nozzle portion, and further comprises an electronic control valve configured to open and close a drug flow path between the drug container and the nozzle portion. According to the present invention, by blocking the drug flow path in advance using the electronic control valve before the pulse-shaped pressure reaches its peak, in a needleless syringe that injects a drug through pulse-shaped pressure application, it is possible to more reliably block external air from entering the nozzle portion during the drug ejection process before the point at which pressurization of the drug is completed.

[0096] According to the needleless syringe of the present invention, by using an electronic control valve with a fast response time, external air can be more reliably blocked from entering the nozzle during the drug discharge process compared to a conventional needleless syringe that only uses a check valve using a ball pin and an elastic member. In addition, according to the present invention, the drug container and the main body are configured to be detachable, and the drug container and the electronic control valve are configured to be detachable, so that the main body and the electronic control valve can be made of permanent parts, while only the drug container can be made of a consumable part, so that a user can easily switch the type of drug discharged from the needleless syringe by replacing only the drug container.

Claims

1. A needleless syringe having a main body, a control unit for controlling the main body, a drug receiving unit connected to one end of the main body, and a nozzle unit for discharging the drug received in the drug receiving unit. The main body part, under the control of the control part, provides a pressure of a predetermined size in the form of a pulse to the drug contained in the drug containing part so that the drug contained in the drug containing part is discharged to the outside through the nozzle hole of the nozzle part. A needleless syringe characterized in that it further comprises an electronic control valve arranged in the drug passage communicating with the drug receiving portion and the nozzle portion, respectively, and configured to open and close the drug passage.

2. In claim 1, A needleless syringe, wherein the control unit controls the electronic control valve to close the drug path by sending a control signal to the electronic control valve at the same time as or before the pressurization of the drug according to the pulse-shaped pressure is completed.

3. In claim 1, The above electronic control valve is configured to be detachably attached to the drug receiving portion and the nozzle portion, respectively, A needleless syringe, wherein the electronic control valve has an internal channel forming a drug channel therein, one end of which is in fluid communication with the internal chamber of the drug receiving portion, and the other end of which is in fluid communication with the nozzle hole of the nozzle portion.

4. In claim 3, A needleless syringe, wherein one end and the other end of the inner passage are formed with a male or female screw portion for screw-connection with the female or male screw portion formed in the nozzle portion and the drug receiving portion, respectively.

5. In claim 3, The above electronic control valve It comprises a first core formed of a magnetic material and a solenoid coil provided to surround the first core, A needleless syringe, wherein the first core is configured to move forward and backward in a direction across the internal path according to the direction of the current applied to the solenoid coil to open and close the internal path.

6. In claim 5, A needleless syringe, wherein the first core further has a sealing portion at the tip thereof along the direction of entry into the internal passage to absorb shock when the first core and the internal passage come into contact to close the internal passage.

7. In claim 5, The above first core has a hollow internal space formed at one end thereof, which is open toward the internal passage, The second core is accommodated in the above inner space, The second core includes an elastic member having one end connected to the internal space and the other end connected to one end of the second core, A needleless syringe, wherein the other end of the second core is configured to contact the inner wall of the inner passage when the first core enters the inner passage and closes the inner passage.

8. In claim 7, A needleless syringe, wherein the other end of the second core further includes a sealing portion for absorbing impact when the second core and the internal passage come into contact.

9. In claim 1, The above nozzle portion is directly connected to the drug receiving portion, The above electronic control valve is configured to be detachable from the nozzle portion, A first passage is formed inside the nozzle part, one end of which communicates with the drug receiving part, and the other end of which communicates with the nozzle hole of the nozzle part. A needleless syringe, wherein the electronic control valve is configured to open and close the flow path of the first passage.

10. In claim 9, The above nozzle part has a second passage extending in a direction crossing the first passage, one end of which is connected to the first passage, and the other end of which is connected to the electronic control valve. The above electronic control valve It comprises a first core formed of a magnetic material and a solenoid coil provided to surround the first core, A needleless syringe, wherein the first core is configured to move forward and backward in a direction crossing the first passage through the second passage according to the direction of the current applied to the solenoid coil, thereby opening and closing the first passage.

11. In claim 10, A needleless syringe, wherein the first core further has a sealing portion at the tip thereof along the direction of entry into the first passage, for absorbing shock when the first core and the first passage come into contact to close the first passage.

12. In claim 10, The first core is formed with a hollow inner space that is open toward the first passage at one end, The second core is accommodated in the above inner space, The second core includes an elastic member having one end connected to the internal space and the other end connected to one end of the second core, A needleless syringe, wherein the other end of the second core is configured to contact the inner wall of the first passage when the first core enters the inner passage and closes the first passage.

13. In claim 12, A needleless syringe, wherein the other end of the second core further includes a sealing portion for absorbing impact when the second core and the internal passage come into contact.

14. In claim 1, A needleless syringe having a one-way check valve on the drug passage so that the drug contained in the chamber of the drug receiving portion flows only in one direction toward the nozzle portion.

15. In claim 5, A needleless syringe, wherein the nozzle portion is detachably mounted to the drug receiving portion.

16. In claim 1, A needleless syringe, wherein the drug receiving portion is detachably mounted on the end of the main body.

17. In any one of claims 6, 8, 11 and 13, A needleless syringe, wherein the sealing portion performs a sealing function to prevent leakage of the drug through the drug passage when the drug passage is closed through the electronic control valve.

Images